Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells
Thomas L. Andersen
Department of Clinical Cell Biology (KCB), Vejle Hospital, CSFU-IRS, University of Southern Denmark
Search for more papers by this authorKent Søe
Department of Clinical Cell Biology (KCB), Vejle Hospital, CSFU-IRS, University of Southern Denmark
Search for more papers by this authorTeis E. Sondergaard
Department of Clinical Cell Biology (KCB), Vejle Hospital, CSFU-IRS, University of Southern Denmark
Search for more papers by this authorTorben Plesner
Department of Hematology, Vejle Hospital, CSFU-IRS, University of Southern Denmark, Vejle, Denmark
Search for more papers by this authorJean-Marie Delaisse
Department of Clinical Cell Biology (KCB), Vejle Hospital, CSFU-IRS, University of Southern Denmark
Search for more papers by this authorThomas L. Andersen
Department of Clinical Cell Biology (KCB), Vejle Hospital, CSFU-IRS, University of Southern Denmark
Search for more papers by this authorKent Søe
Department of Clinical Cell Biology (KCB), Vejle Hospital, CSFU-IRS, University of Southern Denmark
Search for more papers by this authorTeis E. Sondergaard
Department of Clinical Cell Biology (KCB), Vejle Hospital, CSFU-IRS, University of Southern Denmark
Search for more papers by this authorTorben Plesner
Department of Hematology, Vejle Hospital, CSFU-IRS, University of Southern Denmark, Vejle, Denmark
Search for more papers by this authorJean-Marie Delaisse
Department of Clinical Cell Biology (KCB), Vejle Hospital, CSFU-IRS, University of Southern Denmark
Search for more papers by this authorThe project was financially supported be the Danish Research Council and the Danish Cancer Society.
Summary
Osteolytic lesions are a hallmark of multiple myeloma. They are due to the hyperactivity of bone resorbing osteoclasts and hypoactivity of bone forming osteoblasts, in response to neighbouring myeloma cells. This study identified a structure that deeply affects this response, because of its impact on the physical organisation of the myeloma cell microenvironment. The proximity between myeloma cells and osteoclasts or osteoblasts was shown to be conditioned by the recently discovered layer of flat cells that separates the osteoclasts and osteoblasts from the bone marrow, by forming a canopy over bone remodelling compartment (BRC). These canopies are frequently disrupted in myeloma, and this disruption correlates with increased proximity and density of myeloma cells. In vitro evidence indicates that this disruption may be due to direct contact between myeloma and BRC canopy cells. Importantly, this disruption and increased proximity and density of myeloma cells coincides with key myeloma-induced bone events, such as osteolytic lesions, impaired bone formation despite increased bone resorption, and fusion of myeloma cells with osteoclasts thereby forming myeloma-osteoclast hybrid cells. These findings strongly support a critical role of BRC canopies in myeloma-induced bone disease. BRC canopies could therefore be considered as a new therapeutic target.
Supporting Information
Movie S1. 3D-reconstruction of a BRC canopy with minor holes above the OCs.
Movie S2. 3D-reconstruction of a BRC canopy with a larger part missing.
Movie S3. 3D-reconstruction of a disrupted BRC canopy allowing direct contact between MM cells and OCs.
Movie S4. 3D-reconstruction of a disrupted BRC canopy with numerous MM cells within the BRC.
Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.
Filename | Description |
---|---|
BJH_7980_sm_movie_S1.mpg4.1 MB | Supporting info item |
BJH_7980_sm_movie_S2.mpg6.7 MB | Supporting info item |
BJH_7980_sm_movie_S3.mpg21.4 MB | Supporting info item |
BJH_7980_sm_movie_S4.mpg6.1 MB | Supporting info item |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- Abe, M., Hiura, K., Wilde, J., Shioyasono, A., Moriyama, K., Hashimoto, T., Kido, S., Oshima, T., Shibata, H., Ozaki, S., Inoue, D. & Matsumoto, T. (2004) Osteoclasts enhance myeloma cell growth and survival via cell–cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood, 104, 2484–2491.
- Aggarwal, R., Ghobrial, I.A. & Roodman, G.D. (2006) Chemokines in multiple myeloma. Experimental Hematology, 34, 1289–1295.
- Andersen, T.L., Boissy, P., Sondergaard, T.E., Kupisiewicz, K., Plesner, T., Rasmussen, T., Haaber, J., Kolvraa, S. & Delaisse, J.M. (2007) Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: a new type of cancer-host partnership? Journal of Pathology, 211, 10–17.
- Andersen, T.L., Sondergaard, T.E., Skorzynska, K.E., Plesner, T., Plesner, T.L., Hauge, E. & Delaisse, J.M. (2009) A physical mechanism for coupling bone resorption and formation in adult human bone. American Journal of Pathology, 174, 239–247.
- Bataille, R., Chappard, D., Marcelli, C., Dessauw, P., Sany, J., Baldet, P. & Alexandre, C. (1989) Mechanisms of bone destruction in multiple-myeloma – the importance of an unbalanced process in determining the severity of lytic bone-disease. Journal of Clinical Oncology, 7, 1909–1914.
- Bataille, R., Chappard, D., Marcelli, C., Dessauw, P., Baldet, P., Sany, J. & Alexandre, C. (1991) Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple-myeloma. Journal of Clinical Investigation, 88, 62–66.
- Bataille, R., Chappard, D. & Basle, M. (1995) Excessive bone-resorption in human plasmacytomas – direct induction by tumor-cells in-vivo. British Journal of Haematology, 90, 721–724.
- Boissy, P., Andersen, T.L., Abdallah, B.M., KasseM, M., Plesner, T. & Delaisse, J.M. (2005) Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoclast differentiation. Cancer Research, 65, 9943–9952.
- Centrella, M., McCarthy, T.L. & Canalis, E. (1991) Transforming growth factor-beta and remodeling of bone. The Journal of Bone and Joint Surgery. American Volume, 73, 1418–1428.
- Compston, J.E. (2002) Bone marrow and bone: a functional unit. The Journal of Endocrinology, 173, 387–394.
- Ehrlich, L.A., Chung, H.Y., Ghobrial, I., Choi, S.J., Morandi, F., Colla, S., Rizzoli, V., Roodman, G.D. & Giuliani, N. (2005) IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood, 106, 1407–1414.
- Ely, S.A. & Knowles, D.M. (2002) Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. American Journal of Pathology, 160, 1293–1299.
- Epstein, J. & Walker, R. (2006) Myeloma and bone disease: “the dangerous tango”. Clinical Advances in Hematology & Oncology, 4, 300–306.
- Eriksen, E.F., Eghbali-Fatourechi, G.Z. & Khosla, S. (2007) Remodeling and vascular spaces in bone. Journal of Bone and Mineral Research, 22, 1–6.
- Giuliani, N. & Rizzoli, V. (2007) Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma. Leukemia & Lymphoma, 48, 2323–2329.
- Giuliani, N., Colla, S., Morandi, F., Lazzaretti, M., Sala, R., Bonomini, S., Grano, M., Colucci, S., Svaldi, M. & Rizzoli, V. (2005) Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood, 106, 2472–2483.
- Grano, M., Galimi, F., Zambonin, G., Colucci, S., Cottone, E., Zallone, A.Z. & Comoglio, P.M. (1996) Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proceedings of the National Academy of Sciences of the United States of America, 93, 7644–7648.
- Grassi, F., Piacentini, A., Cristino, S., Toneguzzi, S., Cavallo, C., Facchini, A. & Lisignoli, G. (2003) Human osteoclasts express different CXC chemokines depending on cell culture substrate: molecular and immunocytochemical evidence of high levels of CXCL10 and CXCL12. Histochemistry and Cell Biology, 120, 391–400.
- Hauge, E.M., Qvesel, D., Eriksen, E.F., Mosekilde, L. & Melsen, F. (2001) Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. Journal of Bone and Mineral Research, 16, 1575–1582.
- Hayden, J.M., Mohan, S. & Baylink, D.J. (1995) The insulin-like growth factor system and the coupling of formation to resorption. Bone, 17, 93S–98S.
- Hecht, M., Heider, U., Kaiser, M., Von Metzler, I., Sterz, J. & Sezer, O. (2007) Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK. British Journal of Haematology, 138, 446–458.
- Hecht, M., Von, M.I., Sack, K., Kaiser, M. & Sezer, O. (2008) Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA). Experimental Cell Research, 314, 1082–1093.
- Hofbauer, L.C. & Schoppet, M. (2004) Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. Journal of the American Medical Association, 292, 490–495.
- Holt, R.U., Fagerli, U.M., Baykov, V., Ro, T.B., Hov, H., Waage, A., Sundan, A. & Borset, M. (2008) Hepatocyte growth factor promotes migration of human myeloma cells. Haematologica-The Hematology Journal, 93, 619–622.
- Kaiser, M., Mieth, M., Liebisch, P., Oberlander, R., Rademacher, J., Jakob, C., Kleeberg, L., Fleissner, C., Braendle, E., Peters, M., Stover, D., Sezer, O. & Heider, U. (2008) Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. European Journal of Haematology, 80, 490–494.
- Karsdal, M.A., Neutzsky-Wulff, A.V., Dziegiel, M.H., Christiansen, C. & Henriksen, K. (2008) Osteoclasts secrete non-bone derived signals that induce bone formation. Biochemical and Biophysical Research Communications, 366, 483–488.
- Matsumoto, T. & Abe, M. (2006) Bone destruction in multiple myeloma. Skeletal Development and Remodeling in Health, Disease, and Aging, 1068, 319–326.
- Moller, C., Stromberg, T., Juremalm, M., Nilsson, K. & Nilsson, G. (2003) Expression and function of chemokine receptors in human multiple myeloma. Leukemia, 17, 203–210.
- Oshima, T., Abe, M., Asano, J., Hara, T., Kitazoe, K., Sekimoto, E., Tanaka, Y., Shibata, H., Hashimoto, T., Ozaki, S., Kido, S., Inoue, D. & Matsumoto, T. (2005) Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood, 106, 3160–3165.
- Parfitt, A.M. (2000) The mechanism of coupling: a role for the vasculature. Bone, 26, 319–323.
- Sezer, O. (2009) Myeloma bone disease: recent advances in biology, diagnosis, and treatment. Oncologist, 14, 276–283.
- Silvestris, F., Cafforio, P., Tucci, M., Grinello, D. & Dammacco, F. (2003) Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. British Journal of Haematology, 122, 39–52.
- Standal, T., Abildgaard, N., Fagerli, U.M., Stordal, B., Hjertner, O., Borset, M. & Sundan, A. (2007) HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood, 109, 3024–3030.
- Taube, T., Beneton, M.N.C., Mccloskey, E.V., Rogers, S., Greaves, M. & Kanis, J.A. (1992) Abnormal bone remodeling in patients with myelomatosis and normal biochemical indexes of bone-resorption. European Journal of Haematology, 49, 192–198.
- Terpos, E. & Dimopoulos, M.A. (2005) Myeloma bone disease: pathophysiology and management. Annals of Oncology, 16, 1223–1231.
- Tian, E., Zhan, F.H., Walker, R., Rasmussen, E., Ma, Y.P., Barlogie, B. & Shaughnessy, J.D. (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. New England Journal of Medicine, 349, 2483–2494.
- Tinhofer, I., Biedermann, R., Krismer, M., Crazzolara, R. & Greil, R. (2006) A role of TRAIL in killing osteoblasts by myeloma cells. Faseb Journal, 20, 759–761.
- Vallet, S., Raje, N., Ishitsuka, K., Hideshima, T., Podar, K., Chhetri, S., Pozzi, S., Breitkreutz, I., Kiziltepe, T., Yasui, H., Ocio, E.M., Shiraishi, N., Jin, J., Okawa, Y., Ikeda, H., Mukherjee, S., Vaghela, N., Cirstea, D., Ladetto, M., Boccadoro, M. & Anderson, K.C. (2007) MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood, 110, 3744–3752.
- Yaccoby, S., Wezeman, M.J., Henderson, A., Cottler-Fox, M., Yi, Q., Barlogie, B. & Epstein, J. (2004) Cancer and the microenvironment: myeloma–osteoclast interactions as a model. Cancer Research, 64, 2016–2023.
- Yaccoby, S., Ling, W., Zhan, F.H., Walker, R., Barlogie, B. & Shaughnessy, J.D. (2007) Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood, 109, 2106–2111.
- Yu, X., Huang, Y., Collin-Osdoby, P.A. & Osdoby, P.A. (2004) Chemokines acting through CCR1 or CCR5 differentially promote osteoclast recruitment, RANKL development, and function. Journal of Bone and Mineral Research, 19, S413.